Democrats in the Senate are primed this month to make their first attempt at salvaging one of the most popular elements of President Joe Biden’s stalled Build Back Better plan — the proposal to cap insulin costs at $35 a month.
It might not go well.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Congressional legislation in the House would write abortion rights into law in the face of challenges before the Supreme Court.
Nearly two-thirds of those in the coverage gap live in one of three Republican-controlled states, and hospitals fear loss of funding.
Provisions in Democrats' Medicare prescription drug pricing crack open the door to reforms that could have dramatic effects, experts say.
The $3.5 trillion budget plan would be the largest infusion into the American health care system since 2010, but its passage may be difficult.
Late last month Congress passed a nearly 5,600-page legislative package that included $900 billion for urgent pandemic relief, a ban on surprise medical bills and other non-COVID health care issues.
During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is “taking on the big pharmaceutical companies.”
In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor.
For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans’ tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed.